*.- Group Ebitda reached €13 million and total income increased by 11% .
*.- Gross sales of Yondelis® grew by 12% .
Madrid, 27th February 2012:Total income of the Zeltia Group (ZEL.MC) increased by 11% in 2011 to €178,3 million driven by the new agreement with Janssen Pharmaceuticals (Johnson&Johnson) to intensify the development of Yondelis® in the United States.
Zeltia presented a positive net profit of €4,74 million in 2011 (-€7,4 million in
2010). Notably, both operating segments of the Group, biopharma and consumer chemicals, each recorded positive net profit and Ebitda results. The consolidated Ebitda of the Group was €13 million (-€3,97 million in 2010).
Gross sales of Yondelis grew by 12% in 2011 to €80,6 million.
Net sales of Yondelis grew to €74,1 million (€72,3 million in 2010). As a result of the Eurozone crisis and slow consumer consumption, which affected the other business lines of the Group, net consolidated sales were €152,4 million, down 0,7% on 2010 performance. Net sales in the biopharma segment also grew to €80,6 million in 2011 (€79,4 million in 2010) whilst sales in the consumer chemicals segment totalled €71,2 million (73,2 million in 2010).
Investment in R&D totalled €56 million, representing a 1,8% increase year on year.
********************************************+
27 December 2011 :
Pharma Mar, S.A., has come to an agreement with Janssen Products LP, of Janssen Pharmaceutical Companies, on a new action plan to pursue the development of Yondelis in the United States. In this regard Janssen will perform a second pivotal Phase III trial with Yondelis in relapsed ovarian cancer(ROC).
Furthermore, Janssen will continue the Phase III study in L-Sarcoma. Within the frame of said agreement, PharmaMar gets a down-payment of 25 million USDollars before the end of 2011. Additionally PharmaMar will receive another 85 million USDollars for milestones as they are reached, and only based on the development of Yondelis for the period between 2012-2015(25M in 2012, 25M in 2013, 25M in 2014 and 10M in 2015). These milestones are additional to those already included in the original licensing agreement.